NSF SBIR Phase I
Cambridge, MA 07/26/2017 – Elektrofi, Inc. has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $225,000 to conduct research and development (R&D) work on formulating biologics for high concentration, low viscosity subcutaneous administration.
Elektrofi, Inc.’s innovative platform will create a paradigm shift in the delivery of biologics, transforming administration from hours-long IV infusions to seconds-long subcutaneous injections. This solution will enable drug manufacturers to more easily develop breakthrough therapies and profitable products, dramatically improve the convenience and logistics of administration, and improve patient access and affordability to patients
“The National Science Foundation supports small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts,” said Barry Johnson, Director of the NSF’s Division of Industrial Innovation and Partnerships. “We hope that this seed funding will spark solutions to some of the most important challenges of our time across all areas of science and technology.”
Once a small business is awarded a Phase I SBIR/STTR grant (up to $225,000), it becomes eligible to apply for a Phase II grant (up to $750,000). Small businesses with Phase II grants are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.
NSF accepts Phase I proposals from small businesses twice annually in June and December. Small businesses with innovative science and technology solutions, and commercial potential are encouraged to apply. All proposals submitted to the NSF SBIR/STTR program undergo a rigorous merit-based review process.
To learn more about the NSF SBIR/STTR program, visit: www.nsf.gov/SBIR.
About the company: Elektrofi, Inc. is a biotechnology company in Cambridge, MA working on drug delivery.
While biologics are increasingly important to the healthcare system, they remain prohibitively expensive for most patients. One of the chief reasons for the sky-high cost of biologics is the mode of delivery. Because biologics are difficult to concentrate in small volumes, large quantities are often infused into patients. In some cases this means that as much as a liter of drug is administered over a period of up to 10 hours. Not only is this costly, it's highly inconvenient for the patient and the healthcare provider, and it narrows the number of therapies that can actually reach the clinic. In other words, it serves as a barrier to the feasibility of many new drug candidates.
Elektrofi is developing a platform which is capable of concentrating the biologic by up to 100X, and we're using this technology to create a paradigm shift from hours-long infusions to seconds-long injections.
About the National Science Foundation’s Small Business Programs: The National Science Foundation (NSF) awards nearly $190 million annually to startups and small businesses through the Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) program, transforming scientific discovery into products and services with commercial and societal impact. The non-dilutive grants support research and development (R&D) across almost all areas of science and technology helping companies de-risk technology for commercial success. The NSF is an independent federal agency with a budget of about $7 billion that supports fundamental research and education across all fields of science and engineering.